Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity (ADCC), and complement …
S Lohse, S Loew, A Kretschmer… - British Journal of …, 2018 - eprints.soton.ac.uk
British Journal of Haematology, 2018•eprints.soton.ac.uk
Beers, SA, Chan, CH, James, S., French, RR, Attfield, KE, Brennan, CM, Ahuja, A., 9
Shlomchik, MJ, Cragg, MS & Glennie, MJ (2008) Type II (tositumomab) anti-CD20 10
monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion 11
regardless of complement activation. Blood, 112, 4170-4177. 12 13
Shlomchik, MJ, Cragg, MS & Glennie, MJ (2008) Type II (tositumomab) anti-CD20 10
monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion 11
regardless of complement activation. Blood, 112, 4170-4177. 12 13
Beers, SA, Chan, CH, James, S., French, RR, Attfield, KE, Brennan, CM, Ahuja, A., 9 Shlomchik, MJ, Cragg, MS & Glennie, MJ (2008) Type II (tositumomab) anti-CD20 10 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion 11 regardless of complement activation. Blood, 112, 4170-4177. 12 13
eprints.soton.ac.uk
以上显示的是最相近的搜索结果。 查看全部搜索结果